Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(0.98) by 24.49 percent. This is a 75.7 percent increase over losses of $(5.02) per share from the same period last year.
Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(1.22) per share which missed the analyst consensus estimate of $(0.98) by 24.49 percent. This is a 75.7 percent increase over losses of $(5.02) per share from the same period last year.
Comments